The Sarcopenia Study

Sponsor

University of Leicester (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05888688

Collaborator

(none)

Enrollment

Location

Anticipated Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The goal of this cross-sectional study is to investigate the prevalence of sarcopenia in patients with Heart Failure. The main question it aims to answer is:

Whether there is a difference in the prevalence of sarcopenia across the spectrum of HFpEF (Heart failure with preserved ejection fraction) and HFrEF (heart failure with reduced ejection fraction).

This is an observational study. The participant population involves patients with heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. Healthy volunteers will be recruited as controls in addition to adults with asymptomatic Type 2 Diabetes.

Participants will undergo the following:

Skeletal muscle mass, quality and body composition assessments using magnetic resonance imaging (MRI) and bioelectrical impedance analysis (BIA)
Skeletal muscle strength assessments (Dynamometer, FysioMeter, handgrip strength)
Skeletal muscle energetics assessment (31p-Spectroscopy pre/post-exercise recovery)

Researchers will compare Heart failure groups with healthy controls and adults with asymptomatic type 2 Diabetes to see if there are significant differences in the strength, mass and quality of skeletal muscle.

Condition or Disease	Intervention/Treatment	Phase
Heart Failure Sarcopenia Heart Failure With Reduced Ejection Fraction Heart Failure With Preserved Ejection Fraction Type 2 Diabetes Frailty

Detailed Description

Heart failure is a complex condition which affects the hearts' ability to pump blood around the body properly. Due to this complexity, it often affects multiple systems in the body and can impact the quality of life. A proportion of heart failure patients also have muscle weakness, where one can feel fatigued, and weak, and may have trouble balancing and standing. To characterise muscle weakness, it is important to look at skeletal muscle mass, strength, and function. The study will focus on the prevalence of reduced muscle strength or function, using a variety of assessments within patients with heart failure. The prevalence of muscle weakness will be investigated by running assessments to look into muscle strength, a series of simple exercise tests will be run of the calf and thigh, in addition to a walking test, a balance test and a standing test to assess whole body performance. To look at the quality of skeletal muscle, a magnetic resonance imaging (MRI) and spectroscopy session will allow us to investigate the quality of the thigh muscle and the energetics in the calf. Finally, a muscle biopsy will be performed to understand differences in muscle tissue in people with different types of heart failure.

Overall, this study will provide us with unique information on skeletal muscle strength, composition and energetics within patients with heart failure, by looking at the main factors which characterise muscle weakness.

Study Design

Study Type:

Observational [Patient Registry]

Anticipated Enrollment :

80 participants

Observational Model:

Cohort

Time Perspective:

Cross-Sectional

Official Title:

The Imaging Assessment of Sarcopenia Across the Heart Failure Spectrum

Anticipated Study Start Date :

Jun 1, 2023

Anticipated Primary Completion Date :

Sep 1, 2026

Anticipated Study Completion Date :

Sep 1, 2026

Arms and Interventions

Arm	Intervention/Treatment
patients with Heart Failure with Preserved Ejection Fraction (HFpEF) Heart Failure (HF) Patients: Stage A/B HFpEF Established clinical diagnosis of HFpEF (EF>50%) Clinically stable for ≥ 3 months (no admissions to hospital) Age ≥65 Willing to provide written consent for participation in the study.
patients with Heart Failure with Reduced Ejection Fraction (HFrEF) HF Patients: Stage C/D HFpEF and HFrEF Established clinical diagnosis of HFpEF (EF>50%) OR HFrEF (EF<40%) Clinically stable for ≥ 3 months (no admissions to hospital) Age ≥65 Willing to provide written consent for participation in the study.
Asymptomatic T2D Male or female, aged ≥18 and ≤75 years. Diagnosis of stable T2D (determined by i) formal diagnosis in primary care physician case records, ii) a record of diagnostic oral glucose tolerance test OR glycated haemoglobin level ≥6.5%).
Healthy Volunteers Age >18 Able to provide written informed consent

Outcome Measures

Primary Outcome Measures

Volumetric quadriceps skeletal muscle mass (cm^3) [Through study completion, an average of 3 years]
A comparison of volumetric quadriceps skeletal muscle mass (cm3) using MRI between HFpEF and HFrEF patients

Secondary Outcome Measures

HF symptoms and quality of life [Baseline]
Minnesota Living with Heart Failure (MLWHF) questionnaire
Frailty assessment [Baseline]
Edmonton Frail scale
Comparison of Body composition [Baseline]
Bioelectrical impedance analysis (BIA) measure of Appendicular Skeletal muscle (cm^3/height) mass between patient groups
The difference in Muscle fat fraction (percent) [Baseline]
The difference in Muscle fat fraction (%) using MRI (DIXON sequence) of the quadriceps between patient groups
quadriceps Skeletal muscle strength (N) [Baseline]
The difference in quadriceps Skeletal muscle strength (N) between patient groups
Calf plantar flexor strength (N) [Baseline]
The difference in Calf plantar flexor strength (N) (c-station FysioMeter) between patient groups
Handgrip strength (N) [Baseline]
Differences in Handgrip strength (N) (Jamar Dynamometer) between patient groups
A comparison of post-exercise recovery metabolites [Baseline]
A comparison of post-exercise recovery metabolites: Phosphocreatine and inorganic phosphate ratios (PCr/Pi), and Adenosine Triphosphate (ATP) using 31p-Magnetic Resonance Spectroscopy between patient groups
A comparison in distance (metres) walked during 6MWT [Baseline]
A comparison in distance (metres) walked during Six Minute walk test (6MWT) between patient groups
A comparison of daily physical activity [Baseline]
A comparison of daily physical activity behaviours as measured by accelerometry between patient groups
The Short Physical Performance Battery (SPPB) performance [Baseline]
A comparison of lower extremity physical performance following the SPPB test between patient groups
Sarcopenia assessment [Baseline]
SARC-F (Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls) questionnaire

Other Outcome Measures

quadriceps musculoskeletal Biopsy Analysis [Baseline]
RNA sequencing following biopsy acquisition

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Heart Failure (HF) Patients: Stage A/B HFpEF

Established clinical diagnosis of HFpEF (EF>50%)
Clinically stable for ≥ 3 months (no admissions to hospital)
Age ≥65
Willing to provide written consent for participation in the study.

HF Patients: Stage C/D HFpEF and HFrEF

Established clinical diagnosis of HFpEF (EF>50%) OR HFrEF (EF<40%)
Clinically stable for ≥ 3 months (no admissions to hospital)
Age ≥65
Willing to provide written consent for participation in the study. Healthy volunteers
Age >18 2. Able to provide written informed consent Asymptomatic T2D
Male or female, aged ≥18 and ≤75 years.
Diagnosis of stable T2D (determined by i) formal diagnosis in primary care physician case records, ii) a record of diagnostic oral glucose tolerance test OR glycated haemoglobin level ≥6.5%).

Exclusion criteria:

Heart failure

Absolute contraindication to MRI
Inability to walk/undertake the 6-Minute Walk Test (6MWT)
Neuromuscular disorders that may impact skeletal muscle assessment, such as motor neurone disease, multiple sclerosis, skeletal muscle myopathies and myositis
Regular or intermittent oral corticosteroid use
Untreated hyper or hypothyroidism
Heart failure-related hospitalisations in the last 3 months

Healthy volunteers

Previous or current signs of HF
Risk factors for the development of HF, such as hypertension, diabetes Mellitus or coronary artery disease

Asymptomatic Type 2 Diabetes Mellitus (T2D)

Angina pectoris or limiting dyspnoea (>NYHA II)
Major atherosclerotic disease: Symptomatic CAD, history of MI, previous revascularisation, stroke/transient ischaemic attack or symptomatic peripheral vascular disease.
Atrial fibrillation or flutter.
Moderate to severe valvular heart disease.
History of heart failure or cardiomyopathy.
Type 1 diabetes mellitus (T1DM).
Low fasting C-peptide levels suggestive of adult-onset T1DM.
Stage III-V renal disease (estimated glomerular filtration rate ≤30ml/min/1.73m2).
Absolute contraindications to MRI.